Table 1.

Distribution of risk categories according to stage and histology.

LOW RISK	Stage I-II POLEmut Stage IA MMRd/NSMP low-grade EEC with no or focal LVSI
INTERMEDIATE RISK	Stage IB MMRd/NSMP low-grade EEC with no or focal LVSI Stage IA MMRd/NSMP high-grade EEC with no or focal LVSI Stage IA p53abn EEC with no myometrial invasion Stage IA non-endometrioid with no myometrial invasion
HIGH-INTERMEDIATE RISK	Stage I MMRd/NSMP EEC with LVSI Sage IB MMRd/NSMP high-grade EEC Stage II MMRd/NSMP EEC
HIGH RISK	Stage III–IVa EEC with no residual disease Stage I–IVa p53abn EEC with myometrial invasion and no residual disease Stage I–IVa non-endometrioid * with myometrial invasion and no residual disease
ADVANCED/METASTATIC	Stage III–Iva with residual disease Stage IVb

* MMRd and NSMP clear cell carcinomas are not included in any risk category because their biological behavior is undefined.